Finance

Lists
CUV:ASX
Clinuvel Pharmaceuticals Ltd
A$7,54
+0,33%
(+0,025) 1D
9 Nov., 12:34:24 GMT+11  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for CUV...
Open
A$7,42
High
A$7,55
Low
A$7,36
Mkt. cap
380,93 m
Avg. vol.
156,28 k
Volume
40,49 k
Dividend
0,66%
Quarterly dividend
A$0,01
Ex-dividend date
03 Sep. 2026
P/E ratio
11,29
52-wk high
A$13,48
52-wk low
A$6,62
EPS
A$0,67
Shares outstanding
50,49 m
No. of employees
16
Open
A$7,42
High
A$7,55
Low
A$7,36
Mkt. cap
380,93 m
Avg. vol.
156,28 k
Volume
40,49 k
Dividend
0,66%
Quarterly dividend
A$0,01
Ex-dividend date
03 Sep. 2026
P/E ratio
11,29
52-wk high
A$13,48
52-wk low
A$6,62
EPS
A$0,67
Shares outstanding
50,49 m
No. of employees
16
News stories
From web sources and news partners
About Clinuvel Pharmaceuticals Ltd
CEOPhilippe J. Wolgen
Employees16
Founded1987
Headquarters-
SectorHealth Care
Industry-
Websiteclinuvel.com
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in AUD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
18,47 m
18,47 m
28,55 m
28,55 m
Cost of goods sold
2,28 m
2,28 m
5,62 m
5,62 m
Cost of revenue
2,28 m
2,28 m
5,62 m
5,62 m
Research and development expenses
1,70 m
1,70 m
7,35 m
7,35 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,96 m
6,96 m
2,83 m
2,83 m
Operating expense
9,42 m
9,42 m
9,42 m
9,42 m
Total operating expenses
11,71 m
11,71 m
15,04 m
15,04 m
Operating income
6,76 m
6,76 m
13,51 m
13,51 m
Other non operating income
-
-
322,45 k
322,45 k
EBT including unusual items
7,29 m
7,29 m
16,54 m
16,54 m
EBT excluding unusual items
7,29 m
7,29 m
16,54 m
16,54 m
Income tax expense
2,07 m
2,07 m
4,80 m
4,80 m
Effective tax rate
28,39%
28,39%
29,03%
29,03%
Other operating expenses
-1,24 k
-1,24 k
1,24 k
1,24 k
Net income
5,22 m
5,22 m
11,74 m
11,74 m
Net profit margin
28,28%
28,28%
41,11%
41,11%
Earnings per share
-
-
-
-
Interest and investment income
2,63 m
2,63 m
3,87 m
3,87 m
Interest expense
-1,28 m
-1,28 m
-
-
Net interest expenses
1,35 m
1,35 m
3,87 m
3,87 m
Depreciation and amortization charges
250,02 k
250,02 k
-250,02 k
-250,02 k
EBITDA
7,01 m
7,01 m
13,55 m
13,55 m
Gain or loss from assets sale
-
-
28,62 k
28,62 k
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme